Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEMOPTIC is an oral combination product formulated as a tablet containing citicoline, magnesium, and *Ginkgo biloba* extract. It is primarily utilized as a neuroprotective agent in the field of ophthalmology, specifically as an adjunctive therapy for patients with chronic open-angle glaucoma. The formulation aims to preserve visual function and protect the optic nerve from degeneration, complementing conventional intraocular pressure-lowering treatments. Citicoline (cytidine 5'-diphosphocholine) serves as a precursor for the synthesis of phosphatidylcholine, a major component of neuronal membranes, and has demonstrated potential in treating glaucoma, amblyopia, and ischemic optic neuropathies. *Ginkgo biloba* extract provides antioxidant properties and enhances microcirculation, while magnesium acts as a natural antagonist of NMDA receptors to mitigate glutamate-induced excitotoxicity. MEMOPTIC is typically marketed as a dietary supplement or nutraceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MEMOPTIC.